@article {2a958dfc303643bca2b201d067379438,
	title = {The addition of avibactam renders piperacillin an effective treatment for Mycobacterium abscessus infection in an in vivo model},
	journal = {Antimicrobial Resistance and Infection Control},
	volume = {7},
	number = {1},
	year = {2018},
	note = {Publisher Copyright: {\textcopyright} 2018 The Author(s).},
	month = {dec},
	publisher = {BioMed Central Ltd.},
	abstract = {Treating M. abscessus infection is challenging due to the potent β-lactamase Bla Mab (Beta-lactamase of M. abscessus ) . Avibactam is a non-β-lactam, β-lactamase inhibitor shown to inhibit Bla Mab . We tested whether avibactem can render piperacillin effective against M. Abscessus. In-vitro, avibactam enhanced the activity of piperacillin by 16-32 fold, with no significant effect on meropenem. In an in-vivo Galleria mellonella model, meropenem and piperacillin/avibactam significantly decreased infection burden compared to untreated controls. Neither piperacillin nor avibactam alone had a significant effect.},
	keywords = {Avibactam, Combination treatment, MIC, Mycobacterium abscessus, Piperacillin},
	issn = {2047-2994},
	doi = {10.1186/s13756-018-0448-4},
	author = {Michal Meir and Pablo Bifani and Daniel Barkan}
}
